| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | CFO and COO
2 companies
Chevallard Daniel R. is a CFO and COO at VIRX, with reported holdings spanning 2 companies. Recent filings cover 4 purchases and 11 sales. Those positions are worth an estimated $185K at current prices.
Our model assigns Chevallard Daniel R. a middling insider score of 67/100, based on 3 past trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +75.8%.
Chevallard Daniel R.'s largest disclosed position is in LENZ as Chief Financial Officer, worth about $110K. Net of sales, the recent Form 4 record there shows accumulation of 12,886 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 26, 2022 | VIRX Viracta Therapeutics, Inc. | CFO and COO | Sale+OE | 3,596 | $1.90 | $6,836.36 | -4.3% | |
| Feb 28, 2022 | VIRX Viracta Therapeutics, Inc. | CFO and COO | Sale+OE | 3,998 | $2.78 | $11,112.44 | -5.0% | |
| Nov 29, 2021 | VIRX Viracta Therapeutics, Inc. | CFO and COO | Sale+OE | 7,579 | $4.81 | $36,463.76 | -9.4% |